PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
157 hedge funds and large institutions have $438M invested in PDL BioPharma, Inc. in 2019 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 46 increasing their positions, 50 reducing their positions, and 20 closing their positions.
26% more capital invested
Capital invested by funds: $347M → $438M (+$90.7M)
25% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 20
2% more funds holding
Funds holding: 154 → 157 (+3)
8% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$8.3M |
| 2 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
+$5.68M |
| 3 |
WG
Winton Group
London,
United Kingdom
|
+$4.51M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$3.6M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$3.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$21.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5.86M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$4.2M |
| 4 |
KIM
Kestrel Investment Management
San Mateo,
California
|
-$4.01M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$3.04M |
PDLI Hedge Fund Activity: Q1 2019 in Review
157 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q1 2019, worth a combined $438M — up 26% from $347M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new PDLI positions and 20 closed out — a net gain of 5 holders — while 46 added to existing stakes and 50 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $8.3M. The largest seller was Kennedy Capital Management, cutting an estimated $21.7M.
- 157 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q1 2019, up from 154 in Q4 2018.
- Funds reported $438M of PDL BioPharma, Inc. stock for Q1 2019, up 26% quarter-over-quarter.
- 25 funds opened new PDL BioPharma, Inc. positions in Q1 2019 and 20 closed out, a net change of +5 holders.
- The largest PDL BioPharma, Inc. buyer in Q1 2019 was Arrowstreet Capital, an estimated $8.3M added.
- The largest PDL BioPharma, Inc. seller in Q1 2019 was Kennedy Capital Management, an estimated $21.7M sold.
Based on aggregated 13F filings for Q1 2019.